Medico Remedies Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
44.80 -0.79 (-1.73%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
43.32
Today’s High
45.12
52 Week Low
35
52 Week High
92.87
44.51 -1.11 (-2.43%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
43.33
Today’s High
45.45
52 Week Low
34.8
52 Week High
92.95
Key Metrics
- Market Cap (In Cr) 378.57
- Beta -
- Div. Yield (%) 0
- P/B 7.23
- TTM P/E 55.69
- Peg Ratio -6.94
- Sector P/E 31.15
- D/E 0.21
- Open Price 43.32
- Prev Close 45.59
Medico Remedies Analysis
Price Analysis
-
1 Week-25.13%
-
3 Months18.65%
-
6 Month18.8%
-
YTD-45.56%
-
1 Year-40.71%
Risk Meter
- 45% Low risk
- 45% Moderate risk
- 45% Balanced Risk
- 45% High risk
- 45% Extreme risk
Medico Remedies News
GSS Infotech, LANCOR HOLDINGS ORD & others hit 52 week low today ;Check the full list here?
4 min read . 15 May 2024Siemens, Vedanta & others hit 52 week high today ; Do you own any?
4 min read . 15 May 2024LANCOR HOLDINGS ORD, Medico Remedies & others hit 52 week low today ;Check the full list here?
3 min read . 14 May 2024Jindal Steel & Power, Hero Motocorp & others hit 52 week high today ; Do you own any?
3 min read . 14 May 2024Medico Remedies Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 144.92
- Selling/ General/ Admin Expenses Total
- 5.92
- Depreciation/ Amortization
- 2.88
- Other Operating Expenses Total
- 16.18
- Total Operating Expense
- 134.89
- Operating Income
- 10.03
- Net Income Before Taxes
- 11.33
- Net Income
- 8.29
- Diluted Normalized EPS
- 1
- Period
- 2024
- Total Assets
- 96.2
- Total Liabilities
- 43.82
- Total Equity
- 52.37
- Tangible Book Valueper Share Common Eq
- 6.3
- Period
- 2024
- Cashfrom Operating Activities
- 2.44
- Cashfrom Investing Activities
- -2.68
- Cashfrom Financing Activities
- -0.49
- Net Changein Cash
- -0.73
- Period
- 2023
- Total Revenue
- 140.44
- Selling/ General/ Admin Expenses Total
- 5.75
- Depreciation/ Amortization
- 2.72
- Other Operating Expenses Total
- 20.19
- Total Operating Expense
- 133.54
- Operating Income
- 6.9
- Net Income Before Taxes
- 10.1
- Net Income
- 7.24
- Diluted Normalized EPS
- 0.87
- Period
- 2023
- Total Assets
- 87.45
- Total Liabilities
- 43.61
- Total Equity
- 43.84
- Tangible Book Valueper Share Common Eq
- 5.27
- Period
- 2023
- Cashfrom Operating Activities
- 8.17
- Cashfrom Investing Activities
- -6.6
- Cashfrom Financing Activities
- -1.82
- Net Changein Cash
- -0.25
- Period
- 2022
- Total Revenue
- 121.02
- Selling/ General/ Admin Expenses Total
- 5.63
- Depreciation/ Amortization
- 2.08
- Other Operating Expenses Total
- 20.89
- Total Operating Expense
- 115.89
- Operating Income
- 5.13
- Net Income Before Taxes
- 6.55
- Net Income
- 4.89
- Diluted Normalized EPS
- 0.59
- Period
- 2022
- Total Assets
- 76.19
- Total Liabilities
- 38.87
- Total Equity
- 37.32
- Tangible Book Valueper Share Common Eq
- 4.5
- Period
- 2022
- Cashfrom Operating Activities
- 1.71
- Cashfrom Investing Activities
- -2.86
- Cashfrom Financing Activities
- 7.4
- Net Changein Cash
- 6.25
- Period
- 2021
- Total Revenue
- 122.39
- Selling/ General/ Admin Expenses Total
- 4.5
- Depreciation/ Amortization
- 1.65
- Other Operating Expenses Total
- 20.47
- Total Operating Expense
- 118.81
- Operating Income
- 3.58
- Net Income Before Taxes
- 3.69
- Net Income
- 2.59
- Diluted Normalized EPS
- 1.25
- Period
- 2021
- Total Assets
- 75.62
- Total Liabilities
- 43.16
- Total Equity
- 32.46
- Tangible Book Valueper Share Common Eq
- 3.91
- Period
- 2021
- Cashfrom Operating Activities
- -11.31
- Cashfrom Investing Activities
- -16.96
- Cashfrom Financing Activities
- 18.28
- Net Changein Cash
- -9.99
- Period
- 2020
- Total Revenue
- 88.64
- Selling/ General/ Admin Expenses Total
- 3.83
- Depreciation/ Amortization
- 1.66
- Other Operating Expenses Total
- 14.79
- Total Operating Expense
- 87.46
- Operating Income
- 1.18
- Net Income Before Taxes
- 2.22
- Net Income
- 1.63
- Diluted Normalized EPS
- 0.2
- Period
- 2020
- Total Assets
- 75.27
- Total Liabilities
- 45.4
- Total Equity
- 29.87
- Tangible Book Valueper Share Common Eq
- 3.6
- Period
- 2020
- Cashfrom Operating Activities
- 0.97
- Cashfrom Investing Activities
- -3.08
- Cashfrom Financing Activities
- 2.6
- Net Changein Cash
- 0.48
- Period
- 2019
- Total Revenue
- 97.69
- Selling/ General/ Admin Expenses Total
- 3.32
- Depreciation/ Amortization
- 1.51
- Other Operating Expenses Total
- 12.08
- Total Operating Expense
- 96.44
- Operating Income
- 1.25
- Net Income Before Taxes
- 2.18
- Net Income
- 1.57
- Diluted Normalized EPS
- 0.19
- Period
- 2019
- Total Assets
- 76.31
- Total Liabilities
- 48.07
- Total Equity
- 28.24
- Tangible Book Valueper Share Common Eq
- 3.4
- Period
- 2019
- Cashfrom Operating Activities
- 4.9
- Cashfrom Investing Activities
- -4.39
- Cashfrom Financing Activities
- -0.55
- Net Changein Cash
- -0.04
- Period
- 2018
- Total Revenue
- 61.02
- Selling/ General/ Admin Expenses Total
- 3.89
- Depreciation/ Amortization
- 1
- Other Operating Expenses Total
- 10.15
- Total Operating Expense
- 58.55
- Operating Income
- 2.48
- Net Income Before Taxes
- 1.87
- Net Income
- 1.22
- Diluted Normalized EPS
- 0.18
- Period
- 2018
- Total Assets
- 59.39
- Total Liabilities
- 32.72
- Total Equity
- 26.67
- Tangible Book Valueper Share Common Eq
- 3.21
- Period
- 2018
- Cashfrom Operating Activities
- 5.1
- Cashfrom Investing Activities
- -4.98
- Cashfrom Financing Activities
- -0.62
- Net Changein Cash
- -0.5
- Period
- 2024-09-30
- Total Revenue
- 39.35
- Selling/ General/ Admin Expenses Total
- 1.38
- Depreciation/ Amortization
- 0.75
- Other Operating Expenses Total
- 5.31
- Total Operating Expense
- 37.68
- Operating Income
- 1.67
- Net Income Before Taxes
- 2.13
- Net Income
- 1.55
- Diluted Normalized EPS
- 0.19
- Period
- 2024-09-30
- Total Assets
- 99.04
- Total Liabilities
- 43.53
- Total Equity
- 55.51
- Tangible Book Valueper Share Common Eq
- 6.68
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1.4
- Cashfrom Investing Activities
- -1.21
- Cashfrom Financing Activities
- -0.26
- Net Changein Cash
- -0.07
- Period
- 2024-06-30
- Total Revenue
- 30.8
- Selling/ General/ Admin Expenses Total
- 1.44
- Depreciation/ Amortization
- 0.75
- Other Operating Expenses Total
- 4.49
- Total Operating Expense
- 28.74
- Operating Income
- 2.06
- Net Income Before Taxes
- 2.18
- Net Income
- 1.58
- Diluted Normalized EPS
- 0.19
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 41.32
- Selling/ General/ Admin Expenses Total
- 1.36
- Depreciation/ Amortization
- 0.74
- Other Operating Expenses Total
- 4.92
- Total Operating Expense
- 37.41
- Operating Income
- 3.91
- Net Income Before Taxes
- 4.25
- Net Income
- 3.1
- Diluted Normalized EPS
- 0.37
- Period
- 2024-03-31
- Total Assets
- 96.2
- Total Liabilities
- 43.82
- Total Equity
- 52.37
- Tangible Book Valueper Share Common Eq
- 6.3
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 2.44
- Cashfrom Investing Activities
- -2.68
- Cashfrom Financing Activities
- -0.49
- Net Changein Cash
- -0.73
- Period
- 2023-12-31
- Total Revenue
- 29.77
- Selling/ General/ Admin Expenses Total
- 1.72
- Depreciation/ Amortization
- 0.72
- Other Operating Expenses Total
- 3.76
- Total Operating Expense
- 27.76
- Operating Income
- 2.01
- Net Income Before Taxes
- 2.06
- Net Income
- 1.45
- Diluted Normalized EPS
- 0.17
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 42.36
- Selling/ General/ Admin Expenses Total
- 1.48
- Depreciation/ Amortization
- 0.71
- Other Operating Expenses Total
- 3.72
- Total Operating Expense
- 39.99
- Operating Income
- 2.37
- Net Income Before Taxes
- 3.14
- Net Income
- 2.43
- Diluted Normalized EPS
- 0.29
- Period
- 2023-09-30
- Total Assets
- 102.33
- Total Liabilities
- 54.73
- Total Equity
- 47.6
- Tangible Book Valueper Share Common Eq
- 5.72
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 0.66
- Cashfrom Investing Activities
- -0.36
- Cashfrom Financing Activities
- -0.24
- Net Changein Cash
- 0.06
- Period
- 2023-06-30
- Total Revenue
- 31.47
- Selling/ General/ Admin Expenses Total
- 1.36
- Depreciation/ Amortization
- 0.71
- Other Operating Expenses Total
- 3.78
- Total Operating Expense
- 29.73
- Operating Income
- 1.74
- Net Income Before Taxes
- 1.88
- Net Income
- 1.32
- Diluted Normalized EPS
- 0.16
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 27.99
- Selling/ General/ Admin Expenses Total
- 1.27
- Depreciation/ Amortization
- 0.73
- Other Operating Expenses Total
- 3.16
- Total Operating Expense
- 25.45
- Operating Income
- 2.54
- Net Income Before Taxes
- 2.27
- Net Income
- 1.77
- Diluted Normalized EPS
- 0.21
- Period
- 2023-03-31
- Total Assets
- 87.45
- Total Liabilities
- 43.61
- Total Equity
- 43.84
- Tangible Book Valueper Share Common Eq
- 5.27
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 8.17
- Cashfrom Investing Activities
- -6.6
- Cashfrom Financing Activities
- -1.82
- Net Changein Cash
- -0.25
- Period
- 2022-12-31
- Total Revenue
- 38.85
- Selling/ General/ Admin Expenses Total
- 1.72
- Depreciation/ Amortization
- 0.74
- Other Operating Expenses Total
- 5.43
- Total Operating Expense
- 36.19
- Operating Income
- 2.65
- Net Income Before Taxes
- 3.32
- Net Income
- 2.25
- Diluted Normalized EPS
- 0.27
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Medico Remedies Technical
Moving Average
SMA
- 5 Day56.1
- 10 Day57.18
- 20 Day55.29
- 50 Day50.94
- 100 Day45.43
- 300 Day52.11
Medico Remedies Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Gennex Laboratories
- 18.96
- -0.26
- -1.35
- 29
- 13.25
- 431.24
- Venus Remedies
- 297.15
- 2.65
- 0.9
- 429.6
- 280
- 397.29
- Medico Remedies
- 44.8
- -0.79
- -1.73
- 92.87
- 35
- 371.77
- Sanjivani Paranteral
- 284.2
- -5.75
- -1.98
- 360.6
- 122.15
- 332.07
- Fredun Pharmaceuticals
- 672
- -21.45
- -3.09
- 1054
- 650
- 315.78
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Gennex Laboratories
- 27.25
- 2.57
- 9.25
- 8.49
- Venus Remedies
- 13.78
- 0.81
- 7.25
- 5.58
- Medico Remedies
- 45.66
- 7.23
- 13.41
- 3.99
- Sanjivani Paranteral
- 54.95
- 12.14
- -
- 9.41
- Fredun Pharmaceuticals
- 20.86
- 2.68
- 11.15
- 3.37
Medico Remedies Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-Nov-24
- Quarterly Results
- 12-Aug-24
- Quarterly Results
- 09-May-24
- Audited Results
- 12-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 11-May-23
- Audited Results
- 10-Feb-23
- Quarterly Results
- 02-Feb-23
- Stock Split
- 12-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 05-Sept-24
- 20-Aug-24
- AGM
- 24-Aug-23
- 21-Jul-23
- AGM
- 06-Mar-23
- 03-Feb-23
- POM
- 23-Jun-22
- 20-May-22
- POM
- Announced on
- Record Date
- Ex-Bonus
- Description
- 07-Oct-21
- 17-Nov-21
- 16-Nov-21
- Bonus issue of equity shares in the ratio of 3:1 of Rs.. 10/-.
- Ex-Splits
- Old FV
- New FV
- Description
- 16-Mar-23
- 10
- 2
- Stock split from Rs. 10/- to Rs. 2/-.